Australia markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
44.28-0.83 (-1.84%)
At close: 04:00PM EDT
44.98 +0.70 (+1.58%)
After hours: 04:36PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.65B
Enterprise value 3.11B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.50
Price/book (mrq)13.24
Enterprise value/revenue 7.17
Enterprise value/EBITDA -6.03

Trading information

Stock price history

Beta (5Y monthly) 0.66
52-week change 34.29%
S&P500 52-week change 322.64%
52-week high 354.98
52-week low 331.52
50-day moving average 347.82
200-day moving average 342.12

Share statistics

Avg vol (3-month) 3701.83k
Avg vol (10-day) 3848.85k
Shares outstanding 582.34M
Implied shares outstanding 683.88M
Float 872.17M
% held by insiders 14.11%
% held by institutions 1101.19%
Shares short (28 Mar 2024) 43.92M
Short ratio (28 Mar 2024) 45.41
Short % of float (28 Mar 2024) 44.95%
Short % of shares outstanding (28 Mar 2024) 44.76%
Shares short (prior month 29 Feb 2024) 43.87M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -139.70%
Operating margin (ttm)-95.81%

Management effectiveness

Return on assets (ttm)-23.43%
Return on equity (ttm)-193.23%

Income statement

Revenue (ttm)434.25M
Revenue per share (ttm)5.91
Quarterly revenue growth (yoy)23.30%
Gross profit (ttm)N/A
EBITDA -543.2M
Net income avi to common (ttm)-606.64M
Diluted EPS (ttm)-8.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)577.21M
Total cash per share (mrq)7.01
Total debt (mrq)934.74M
Total debt/equity (mrq)339.39%
Current ratio (mrq)2.61
Book value per share (mrq)3.35

Cash flow statement

Operating cash flow (ttm)-474.81M
Levered free cash flow (ttm)-312.22M